enGene Therapeutics Inc. Common Stock ENGN
i
Market datapartial · fetched 2026-11-07T01:00:52.464Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-06T21:00:00.597426946Z
FundamentalsAlpha Vantage · unavailable
enGene Therapeutics Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | 2.06 | 800.0% | 75.5% | |||
| 30Δ | 2.63 | 800.0% | 61.0% | |||
| 35Δ | ||||||
| 40Δ | 2.76 | 359.1% | 71.6% | |||
| 45Δ | 2.44 | 328.4% | 54.5% | |||
| 50Δ | 2.11 | 297.6% | 37.4% | |||
| 55Δ | 1.92 | 281.5% | 29.1% | |||
| 60Δ | 1.80 | 273.2% | 25.5% | |||
| 65Δ | 1.69 | 264.8% | 22.0% | |||
| 70Δ | 1.57 | 256.4% | 18.4% | |||
| 75Δ | 1.45 | 248.0% | 14.9% | |||
| 80Δ | 1.33 | 239.6% | 11.3% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.06
- IV
- 800.0%
- B/E move
- 75.5%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.63
- IV
- 800.0%
- B/E move
- 61.0%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
40Δ
- Pseudo strike
- 2.76
- IV
- 359.1%
- B/E move
- 71.6%
- Pseudo strike
- IV
- B/E move
45Δ
- Pseudo strike
- 2.44
- IV
- 328.4%
- B/E move
- 54.5%
- Pseudo strike
- IV
- B/E move
50Δ
- Pseudo strike
- 2.11
- IV
- 297.6%
- B/E move
- 37.4%
- Pseudo strike
- IV
- B/E move
55Δ
- Pseudo strike
- 1.92
- IV
- 281.5%
- B/E move
- 29.1%
- Pseudo strike
- IV
- B/E move
60Δ
- Pseudo strike
- 1.80
- IV
- 273.2%
- B/E move
- 25.5%
- Pseudo strike
- IV
- B/E move
65Δ
- Pseudo strike
- 1.69
- IV
- 264.8%
- B/E move
- 22.0%
- Pseudo strike
- IV
- B/E move
70Δ
- Pseudo strike
- 1.57
- IV
- 256.4%
- B/E move
- 18.4%
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- 1.45
- IV
- 248.0%
- B/E move
- 14.9%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 1.33
- IV
- 239.6%
- B/E move
- 11.3%
- Pseudo strike
- IV
- B/E move
Options history
No recorded observations
Biotechnology
ENTA
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company is…
More →ENTX
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally administered large molecule therapies for unmet medical…
More →ERAS
Erasca Inc. is a pioneering biopharmaceutical firm specializing in the development of targeted therapies for genetically defined cancers, aiming to meet significant unmet needs in…
More →EVMN
Evommune, Inc. is an innovative biotechnology company focused on developing cutting-edge therapeutics for immunological disorders, targeting significant unmet medical needs in…
More →EWTX
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The company is headquartered in Boulder, Colorado.
More →EXEL
Exelixis, Inc., an oncology-focused biotechnology company, is focused on the discovery, development, and commercialization of new drugs to treat cancers in the United States. The…
More →